Avadel Pharmaceuticals

Avadel Pharmaceuticals reported a significant increase in LUMRYZ sales, with Q4 2024 net revenue of $50.0 million, over 150% growth from 2023. By December 31, 2024, 2,500 patients were on LUMRYZ, aiming for $240-$260 million revenue in 2025. The company plans to enhance LUMRYZ's market presence and patient experience.

Avadel Pharmaceuticals reported a significant increase in LUMRYZ™ sales, with Q4 2024 net revenue of approximately $50.0 million, a 150% increase from 2023. By December 31, 2024, 2,500 patients were on LUMRYZ, with 600 initiating therapy in Q4. The company forecasts 2025 net product revenue between $240 - $260 million, aiming for 50% year-over-year growth. Avadel is advancing its Phase 3 trial for idiopathic hypersomnia and developing a low-/no-sodium oxybate formulation.

Avadel Pharmaceuticals reported a significant increase in LUMRYZ™ sales, with Q4 2024 net revenue of approximately $50.0 million, over 150% growth from Q4 2023. By December 31, 2024, 2,500 patients were on LUMRYZ, with 600 initiating therapy in Q4. The company anticipates $240 – $260 million in net product revenue for 2025, aiming for 50% year-over-year growth. Avadel is enhancing its commercial strategy to expand LUMRYZ's market reach and improve patient experience.

The REVITALYZ Phase 3 study for LUMRYZ in IH is ongoing, with completion expected in late 2025. Preclinical work continues on a low-/no-sodium oxybate formulation. 2025 guidance is preliminary, based on current market views and assumptions, with actual results potentially varying.

Avadel Pharmaceuticals reported a significant increase in LUMRYZ™ sales, with Q4 2024 net revenue of ~$50.0M, up over 150% from 2023. By Dec 31, 2024, 2,500 patients were on LUMRYZ, aiming for $240-260M in 2025 revenue. The company focuses on narcolepsy treatment, with ongoing Phase 3 trials for idiopathic hypersomnia.

Avadel Pharmaceuticals reported Q4 2024 LUMRYZ net revenue of $50.0M, a 150% increase from Q4 2023. Full-year 2024 revenue was $169.0M, with 2025 guidance at $240–$260M. 2,500 patients were on LUMRYZ by end-2024, aiming for 3,300–3,500 by end-2025. Phase 3 REVITALYZ study completion expected H2 2025.

Avadel Pharmaceuticals reported significant growth in LUMRYZ™ sales, with $50M in Q4 2024, a 150% increase from 2023, and 2,500 patients by year-end. Projected 2025 revenue is $240-260M, a 50% growth. FDA approved LUMRYZ for narcolepsy treatment, granting exclusivity until 2031. Avadel also announced employee inducement awards and plans for corporate updates.

Avadel Pharmaceuticals plc announced a conference call and webcast on January 8, 2025, to discuss its Q4 and full-year 2024 preliminary financial results. The event will be accessible via the company's website, with a replay available for 90 days. Avadel focuses on innovative medication development, including its FDA-approved product LUMRYZ™ for narcolepsy treatment.

In 2024, NeurologyLive® highlighted neurology advancements, focusing on sleep disorders. Key updates included FDA approvals for narcolepsy treatments, promising phase 3 trial results for sleep apnea, and a deep learning model predicting cognitive status from sleep EEG data. Light therapy showed benefits for Alzheimer's disease symptoms.

Axsome Therapeutics' AXS-12 met primary endpoint in Phase III ENCORE trial, reducing cataplexy attacks by 72% at one month and 82% at six months. The company plans to submit an NDA to the FDA.